Shares of Harrow Health (NASDAQ: HROW) were down more than 24% as of 1:45 p.m. ET Friday after the company reported first-quarter earnings following the close of trading Thursday. The pharmaceutical company focuses on eye therapies. The company's stock is still up by around 39% so far this year.

The company reported a first-quarter loss of $6.6 million after losing $2.4 million in the same quarter a year ago, but there was positive news in the report. It set a quarterly record for revenue -- $26.1 million, up 28% sequentially and 18% year over year. 

CEO Mark L. Baum said the company expects the revenue growth from its branded pharmaceutical products will "meaningfully outpace" sales growth for its compounded pharmaceutical products. The company also reaffirmed its revenue guidance range of $135 million to $143 million for 2023, representing a climb of 52% to 61% over 2022. The company also said it expects between $44 million to $50 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) this year.

Continue reading

Source Fool.com